Overview

* Women's health company Hologic's ( HOLX ) fiscal Q4 rev grows 6.2% yr/yr, beating analyst expectations

* Non-GAAP EPS for fiscal Q4 beats consensus, increasing 11.9%

* Company to be acquired by Blackstone and TPG for up to $79 per share

Outlook

* Company is not providing guidance due to acquisition by Blackstone and TPG

Result Drivers

* DIAGNOSTICS GROWTH - Higher core U.S. molecular diagnostics sales drove diagnostics revenue growth, offset by lower COVID-19 assay sales and reduced sales in China

* BREAST HEALTH - Growth driven by strong interventional product sales and improved U.S. sales execution

* SURGICAL REVENUE - Increased sales of MyoSure and Fluent, and contributions from Gynesonics acquisition boosted surgical revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Beat $1.04 $1.03

Revenue bln bln (13

Analysts

)

Q4 Beat $1.13 $1.10

Adjusted (14

EPS Analysts

)

Q4 EPS $0.83

Q4 Beat $254.70 $246.10

Adjusted mln mln (12

Net Analysts

Income )

Q4 Beat $347 mln $346.05

Adjusted mln (11

EBITDA Analysts

)

Q4 60.90%

Adjusted

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 15 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Hologic Inc ( HOLX ) is $75.50, about 2.1% above its October 31 closing price of $73.91

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)